

behind every great company
lies an abundance of great life stories



PRESS RELEASE 22/7/2011:

A new distinction for ELPEN

ELPEN was awarded on June 28th, at the STATBANK event hosted by the American College of Classical Studies, an award presented to the company by the Business Guide “**Diamonds 2011**”, as one of the most “**Admired Enterprises of 2011**”.

In 1965, Dimitrios Pentafragas, a graduate of Pharmacy, founded ELPEN embarking thus on a challenging, difficult, journey with the objective to establish a pioneer pharmaceutical company in Greece which would become a worthy competitor, and in the future even a collaborator, of important multinationals!

The Chairman chose to establish a company which with great focus and determination would produce the highest of quality products, and over the years he managed to win over the trust and respect of the local medical and pharmaceutical communities. In time, ELPEN was established as a local company with functions and pursuits comparable only to multinationals!

During this very dramatic period of economic recession, ELPEN Group provides added value to the Greek economy, by means of the company’s ambitious endeavors in technology, exports, and its many distinctions from the local and international business sector.

During our company’s recent grand opening of the new Experimental Research Center headquarters, Sir Magdi Yacoub himself expressed his profound admiration for the substantial work carried out at the Center, calling it a “fantastic and novel project”.

Presently, ELPEN Group employs 720 people with an annual turnover of 170 million euros (2010), is ranked in the 7th position among the 300 pharmaceutical companies active in Greece, while maintaining a huge lead among the absolutely Greek pharmaceutical companies as ELPEN has ranked 1st for many years.

Considering the predicament of Greece during this bleak economic crisis, ELPEN is adamant in its objective to maintain the number of jobs, refusing to downsize, and has even broadened its business endeavors by investing substantially in programs covering 30 countries, such as in the advanced markets of western Europe (Italy, Germany, and the UK), in Asia (Singapore, the Philippines), and in Africa (S.Africa). Moreover, ELPEN has established important exporting networks in Rumania and Turkey.

Our company’s export activities are expected to soar due to our important collaborations regarding our ELPENHALER[®], our novel, patent-protected, proprietary dry powder inhaler device, which is the invention of our Chairman and Founder Dimitrios Pentafragas, intended for the treatment of asthma and COPD. The device is patent-protected in over 100 countries.



behind every great company
lies an abundance of great life stories

ELPEN

The logo for ELPEN features the word "ELPEN" in a large, bold, black, sans-serif font. The letters are stacked vertically, with the top half of each letter being solid black and the bottom half being a lighter, semi-transparent grey. To the right of the word, there is a small, stylized green leaf with three leaves and a stem.

ELPEN is a pharmaceutical company that for nearly half a century has managed to achieve what every Greek business envisions for the 'new Greece'. ELPEN's success is a testimonial to the greatness that can be achieved in all sectors of Industry in Greece. It is living proof that Greek companies can in fact become leaders in their country, that they can export, they can invest in high-level research and development, they can build and maintain state-of-the-art manufacturing facilities, and most importantly, that they can provide employment in Greece offering added value to the Greek economy, and thus, become worthy competitors and even collaborators of behemoth multinationals!

